| Identification | Back Directory | [Name]
Miriplatin | [CAS]
141977-79-9 | [Synonyms]
Miripla
SM 11355
[(1R,2R)-1,2-Cyclohexanediamine]bis(myristato)platinum
(SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-kappaN,kappaN'])bis(myristato-kappaO)platinum
(SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-kappaN,kappaN'])bis(myristato-kappaO)platinum(II) | [Molecular Formula]
C34H68N2O4Pt | [MOL File]
141977-79-9.mol | [Molecular Weight]
762 |
| Chemical Properties | Back Directory | [storage temp. ]
Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | [solubility ]
DMF : < 1 mg/mL (insoluble) | [form ]
Solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Miplatin is a platinum-based anticancer drug developed by Japan's Sumitomo Pharmaceutical Co., Ltd. It is used in the treatment of liver cancer, malignant lymphoma, non-small cell lung cancer, small cell lung cancer and superficial bladder cancer. | [Biological Activity]
Miriplatin (SM-11355) is a derivative of cisplatin containing myristate as a carrier ligand. It is a novel lipophilic platinum complex for the treatment of hepatocellular carcinoma. | [in vitro]
Miriplatin (SM-11355) suspended in LPD (miriplatin/LPD, 100 μg/mL) inhibits the growth of AH109A cells, forms platinum-DNA adducts, and induces apoptosis. < b> | [in vivo]
Miriplatin (SM-11355) (0.02-0.4 mg/20 μL) in lipiodol reduces tumor growth rates in a dose dependent manner in rats bearing AH109A tumor cells. Miriplatin/LPD (400 μg/head) significantly reduces tumor growth rates the growth of tumor in rats bearing AH109A cells. |
|
|